Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Taiyen Biotech Co., Ltd. (1737:TWSE), powered by AI.
Taiyen Biotech Co., Ltd. is currently trading at $31.75. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Taiyen Biotech Co., Ltd. on Alpha Lenz.
View Taiyen Biotech Co., Ltd.'s valuation metrics on Alpha Lenz.
“Taiyen Biotech Co., Ltd.'s ROE is 5.9%. Explore profitability and growth together.”
Ask for details →Taiyen Biotech Co., Ltd. is a leading biotechnology company that engages in the research, development, and production of a wide array of biotechnological products. Initially recognized for its development of essential healthcare commodities, Taiyen Biotech has expanded its portfolio to include a diverse range of health, beauty, and wellness products. The company is particularly noted for its expertise in marine-based biotechnologies, leveraging natural resources to innovate in the realms of skincare, nutritional supplements, and pharmaceuticals. With a focus on sustainability and environmental responsibility, Taiyen Biotech plays a crucial role in several industries—most prominently in healthcare and consumer goods. The company’s strategic initiatives often involve partnerships and collaborations that enhance its footprint in the biotechnology sector. In the financial markets, Taiyen Biotech is regarded as a key player within the biotechnology industry, offering insights into the intersection of natural resources and advanced scientific research, and contributing significantly to advancements in consumer health and wellness products. Headquartered in Taiwan, Taiyen Biotech continues to influence global biotech trends with its innovative approach to product development.
“Taiyen Biotech Co., Ltd.'s ROE is 5.9%. Explore profitability and growth together.”
Ask for details →Taiyen Biotech Co., Ltd. (ticker: 1737) is a company listed on TWSE in the Consumer Defensive sector (Household & Personal Products).
The current price is 31.75 with a P/E ratio of -x and P/B of -x.
ROE is 5.93% and operating margin is 14.10%. Annual revenue is $3.3B.